Therapeutic strategies for Alzheimer's disease

Nature Reviews Drug Discovery

Volumn 1, Issue 11, 2002, Pages 859-866

  Wolfe, Michael S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BENZODIAZEPINE DERIVATIVE; BETA SECRETASE; CHOLINESTERASE INHIBITOR; CLIOQUINOL; COPPER; ENZYME INHIBITOR; GAMMA SECRETASE; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTAM DERIVATIVE; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M3 RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; NOTCH RECEPTOR; PEPTIDE DERIVATIVE; PPI 1019; PPI 368; PRESENILIN 1; PRESENILIN 2; STEROID; SULFONAMIDE; TAU PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC;

ALZHEIMER DISEASE; DISEASE COURSE; DRUG ACTIVITY; DRUG MECHANISM; FATALITY; HUMAN; LONG TERM POTENTIATION; NEUROFIBRILLARY TANGLE; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; DRUG ANTAGONISM; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; HUMANS;

EID: 0036833437     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd938     Document Type: Review

References (96)

1. Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356 (2002).
2. Esler, W. P. & Wolfe, M. S. A portrait of Alzheimer secretases - new features and familiar faces. Science 293, 1449-1454 (2001).
3. Goate, A. et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706 (1991).
4. Chartier-Harlin, M. C. et al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature 353, 844-846 (1991).
5. Murrell, J., Farlow, M., Ghetti, B. & Benson, M. D. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 254, 97-99 (1991).
6. Selkoe, D. J. Cell biology of the amyloid-β protein precursor and the mechanism of Alzheimer's disease. Annu. Rev. Cell Biol. 10, 373-403 (1994).
7. Suzuki, N. et al. An increased percentage of long amyloid-β protein secreted by familial amyloid-β protein precursor (β-APP717) mutants. Science 264, 1336-1340 (1994).
8. Eckman, C. B. et al. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of Aβ42(43). Hum. Mol. Genet. 6, 2087-2089 (1997).
9. Sherrington, R. et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754-760 (1995).
10. Levy-Lahad, E. et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269, 973-977 (1995).
11. Rogaev, E. I. et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376, 775-778 (1995).
12. Scheuner, D. et al. Secreted amyloid-β protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med. 2, 864-870 (1996).
13. Duff, K. et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature 383, 710-713 (1996).
14. 42 deposition and severe cerebellar pathology. Nature Med. 2, 1146-1150 (1996).
15. Citron, M. et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid-β protein in both transfected cells and transgenic mice. Nature Med. 3, 67-72 (1997).
16. Tomita, T. et al. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid-β protein ending at the 42nd (or 43rd) residue. Proc. Natl Acad. Sci. USA 94, 2025-2030 (1997).
17. Borchelt, D. R. et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron 17, 1005-1013 (1996).
18. Wolfe, M. S. Secretase targets for Alzheimer's disease: identification and therapeutic potential. J. Med. Chem. 44, 2039-2060 (2001).
19. Vassar, R. et al. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741 (1999).
20. Sinha, S. et al. Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature 402, 537-540 (1999).
21. Yan, R. et al. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity. Nature 402, 533-537 (1999 ).
22. Hussain, I. et al. Identification of a novel aspartic protease (ASP2) as β-secretase. Mol. Cell. Neurosci. 14, 419-427 (1999).
23. Hong, L. et al. Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor. Science 290, 150-153 (2000).
24. Ghosh, A. K. et al. Structure-based design: potent inhibitors of human brain memapsin 2 (β-secretase). J. Med. Chem. 44, 2865-2868 (2001).
25. Kitazume, S. et al. Alzheimer's β-secretase, β-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. Proc. Natl Acad. Sci. USA 98, 13554-13559 (2001).
26. Luo, Y. et al. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation. Nature Neurosci. 4, 231-232 (2001).
27. Cai, H. et al. BACE1 is the major β-secretase for generation of Aβ peptides by neurons. Nature Neurosci. 4, 233-234 (2001).
28. Wolfe, M. S. et al. Peptidomimetic probes and molecular modeling suggest Alzheimer's γ-secretases are intramembrane-cleaving aspartyl proteases. Biochemistry 38, 4720-4727 (1999).
29. Shearman, M. S. et al. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid-β protein precursor γ-secretase activity. Biochemistry 39, 8698-8704 (2000).
30. Herreman, A. et al. Total inactivation of γ-secretase activity in presenilin-deficient embryonic stem cells. Nature Cell Biol. 2, 461-462 (2000).
31. Zhang, Z. et al. Presenilins are required for γ-secretase cleavage of β-APP and transmembrane cleavage of Notch-1. Nature Cell Biol. 2, 463-465 (2000).
32. Wolfe, M. S. et al. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature 398, 513-517 (1999).
33. Yu, G. et al. The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains β-catenin. J. Biol. Chem. 273, 16470-16475 (1998).
34. Thinakaran, G. et al. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 17, 181-190 (1996).
35. Capell, A. et al. The proteolytic fragments of the Alzheimer's disease-associated presenilin-1 form heterodimers and occur as a 100-150-kDa molecular mass complex. J. Biol. Chem. 273, 3205-3211 (1998).
36. Ratovitski, T. et al. Endoproteolytic processing and stabilization of wild-type and mutant presenilin. J. Biol. Chem. 272, 24536-24541 (1997).
37. Steiner, H. et al. Expression of Alzheimer's disease-associated presenilin-1 is controlled by proteolytic degradation and complex formation. J. Biol. Chem. 273, 32322-32331 (1998).
38. Thinakaran, G. et al. Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors. J. Biol. Chem. 272, 28415-28422 (1997).
39. Li, Y. M. et al. Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405, 689-694 (2000).
40. Esler, W. P. et al. Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1. Nature Cell Biol. 2, 428-434 (2000).
41. Li, Y. M. et al. Presenilin 1 is linked with γ-secretase activity in the detergent solubilized state. Proc. Natl Acad. Sci. USA 97, 6138-6143 (2000).
42. Esler, W. P. et al. Activity-dependent isolation of the presenilin/γ-secretase complex reveals nicastrin and a γ substrate. Proc. Natl Acad. Sci. USA 99, 2720-2725 (2002).
43. Yu, G. et al. Nicastrin modulates presenilin-mediated Notch/Glp-1 signal transduction and β-APP processing. Nature 407, 48-54 (2000).
44. Goutte, C., Tsunozaki, M., Hale, V. A. & Priess, J. R. APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc. Natl Acad. Sci. USA 99, 775-779 (2002).
45. Francis, R. et al. APH-1 and PEN-2 are required for Notch pathway signaling, γ-secretase cleavage of β-APP, and presenilin protein accumulation. Dev. Cell 3, 85-97 (2002).
46. Seiffert D. et al. Presenilin-1 and -2 are molecular targets for γ-secretase inhibitors. J. Biol. Chem. 275, 34086-34091 (2000).
47. Dovey, H. F. et al. Functional γ-secretase inhibitors reduce β-amyloid peptide levels in brain. J. Neurochem. 76, 173-181 (2001).
48. Hadland, B. K. et al. γ-Secretase inhibitors repress thymocyte development. Proc. Natl Acad. Sci. USA 98, 7487-7491 (2001).
49. Doerfler, P., Shearman, M. S. & Perlmutter, R. M. Presenilin-dependent γ-secretase activity modulates thymocyte development. Proc. Natl Acad. Sci. USA 98, 9312-9317 (2001).
50. 42 independently of cyclooxygenase activity. Nature 414, 212-216 (2001).
51. Hung, A. Y. et al. Activation of protein kinase C inhibits cellular production of the amyloid β-protein. J. Biol. Chem. 268, 22959-22962 (1993).
52. Buxbaum, J. D., Koo, E. H. & Greengard, P. Protein phosphorylation inhibits production of Alzheimer amyloid β/A4 peptide. Proc. Natl Acad. Sci. USA 90, 9195-9198 (1993).
53. Felsenstein, K. M., Ingalls, K. M., Hunihan, L. W. & Roberts, S. B. Reversal of the Swedish familial Alzheimer's disease mutant phenotype in cultured cells treated with phorbol 12,13-dibutyrate. Neurosci. Lett. 174, 173-176 (1994).
54. Jacobsen, J. S. et al. The release of Alzheimer's disease β-amyloid peptide is reduced by phorbol treatment. J. Biol. Chem. 269, 8376-8382 (1994).
55. Nitsch, R. M., Slack, B. E., Wurtman, R. J. & Growdon, J. H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258, 304-307 (1992).
56. 1-selective agonist AF102B. Biochem. Biophys. Res. Commun. 203, 652-658 (1994).
57. Wolf, B. A. et al. Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid β-protein production in human neuronal NT2N cells. J. Biol. Chem. 270, 4916-4922 (1995).
58. Lin, L., Georgievska, B., Mattsson, A. & Isacson, O. Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation. Proc. Natl Acad. Sci. USA 96, 12108-12113 (1999).
59. Corder, E. H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923 (1993).
60. Corder, E. H. et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genet. 7, 180-184 (1994).
61. Kivipelto M. et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. Br. Med. J. 322, 1447-1451 (2001).
62. Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G. G. & Siegel, G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439-1443 (2000).
63. Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. & Drachman, D. A. Statins and the risk of dementia. Lancet 356, 1627-1631 (2000).
64. Sparks, D. L. et al. Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126, 88-94 (1994).
65. Simons, M. et al. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc. Natl Acad. Sci. USA 95, 6460-6464 (1998).
66. 40 in vitro and in vivo. Proc. Natl Acad. Sci. USA 98, 5856-5861 (2001).
67. Kojro E., Gimpl, G., Lammich, S., Marz, W. & Fahrenholz, F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM10. Proc. Natl Acad. Sci. USA 98, 5815-5820 (2001).
68. Puglielli, L. et al. Acyl-coenzyme A:cholesterol acyltransferase modulates the generation of the amyloid β-peptide. Nature Cell Biol. 3, 905-912 (2001).
69. Pike, C. J., Burdick, D., Walencewicz, A. J., Glabe, C. G. & Cotman, C. W. Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13, 1676-1687 (1993).
70. Lorenzo, A. & Yankner, B. A. β-Amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl Acad. Sci. USA 91, 12243-12247 (1994).
71. Hartley, D. M. et al. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19, 8876-8884 (1999).
72. Jarrett, J. T., Berger, E. P. & Lansbury, P. T. Jr. The carboxy terminus of the β-amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32, 4693-4697 (1993).
73. Harper, J. D., Wong, S. S., Lieber, C. M. & Lansbury, P. T. Observation of metastable Aβ amyloid protofibrils by atomic force microscopy. Chem. Biol. 4, 119-125 (1997).
74. Walsh, D. M., Lomakin, A., Benedek, G. B., Condron, M. M. & Teplow, D. B. Amyloid-β protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 272, 22364-22372 (1997).
75. Walsh, D. M. et al. Naturally secreted oligomers of amyloid-β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002).
76. Findeis, M. A. Peptide inhibitors of β-amyloid aggregation. Curr. Top. Med. Chem. 2, 417-423 (2002).
77. Permanne, B. et al. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a β-sheet breaker peptide. FASEB J. 16, 860-862 (2002).
78. Bush, A. I. & Tanzi, R. E. The galvanization of β-amyloid in Alzheimer's disease. Proc. Natl Acad. Sci. USA 99, 7317-7319 (2002).
79. Cherny, R. A. et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 665-676 (2001).
80. Lee, J. Y., Cole, T. B., Palmiter, R. D., Suh, S. W. & Koh, J. Y. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc. Natl Acad. Sci. USA 99, 7705-7710 (2002).
81. Schenk, D. et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177 (1999).
82. Weiner, H. L. et al. Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. 48, 567-579 (2000).
83. Morgan, D. et al. Aβ-peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985 (2000).
84. Janus, C. et al. Aβ-peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982 (2000).
85. Bard, F. et al. Peripherally administered antibodies against amyloid-β peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med. 6, 916-919 (2000).
86. DeMattos, R. B. et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 98, 8850-8855 (2001).
87. Dodart, J. C. et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nature Neurosci. 5, 452-457 (2002).
88. Rogers, J. T. et al. Alzheimer's disease drug discovery targeted to the APP mRNA 5′ untranslated region. J. Mol. Neurosci. 19, 77-82 (2002).
89. Rogers, J. T. et al. An iron-responsive element type II in the 5′ untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. 2002 Aug 26 (doi: 10.1074/jbc.M207435200).
90. Selkoe, D. J. Clearing the brain's amyloid cobwebs. Neuron 32, 177-180 (2001).
91. Pepys, M. B. et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417, 254-259 (2002).
92. Edbauer, D., Winkler, E., Haass, C. & Steiner, H. Presenilin and nicastrin regulate each other and determine amyloid beta-peptide production via complex formation. Proc. Natl Acad Sci USA 99, 8666-8671 (2002).
93. Yang, D. S. et al. Mature glycosylation and trafficking of nicastrin modulate its binding to presinilins. J. Biol. Chem. 277, 28135-28142 (2002).
94. Leem, J. Y. et al. Presenilin 1 is required for maturation and cell surface accumulation of nicastrin. J. Biol. Chem. 277, 19236-19240 (2002).
95. Kimberly, W. T. et al. Complex N-linked glycosylated nicastrin associates with active g-secretase and undergoes tight cellular regulation. J. Biol. Chem. 277, 35113-35117 (2002).
96. Wahrle, S. et al. Cholesterol-dependent γ-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Dis. 9, 11-23 (2002).